HOOKIPA Pharma Inc. (NASDAQ:HOOK) Q4 2022 Earnings Call Transcript

So, you’re asking a complex question. At this point in time, we’re very, very happy about our collaborations with Roche and Gilead. We can see that as our datasets mature and the strength of the technology gets more and more proven, other people could be interested and we would not be adverse to partnering. At the same time, we do know that retaining value in the Company is important. And therefore, we would have to look at it at the moment that such partnership discussions come up.

Operator: And there are no further questions at this time. I would like to turn the conference back over to management for any additional or closing remarks.

Joern Aldag: Very briefly, I think we’ve had a great year 2022. We’re gearing up to some important value inflection points and milestones and are looking forward and curious to see the outcome of all of this. And would basically tell our shareholders that we’re doing our utmost to keep our burn low up until better times and help the markets to really progress the Company to big value inflection points that will change its valuation and with that the future. Thanks a lot and talk to you soon. Bye, bye.

Operator: And that does conclude today’s conference. Thank you for your participation. You may now disconnect.